Drugs Made In America Acquisition DMIIU Institutional Ownership

Updated Oct 16, 2026

Drugs Made in America Acquisition II Corp. (NASDAQ:DMIIU) had 11 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Total holdings of Drugs Made in America Acquisition shares fell 20.84% compared with Q1 2026.
• Looking at the 11 holders of DMIIU individually, 1 added to its position, 3 reduced their stakes and 7 left their positions unchanged.
• Institutional investors held 3.45Mn shares of Drugs Made in America Acquisition in total at the end of Q2 2026, down 906.89K from the prior quarter.
• LMR Partners LLP was the top holder of Drugs Made in America Acquisition as of June 30, 2026, with 2Mn shares.
• The holder that added the most shares of Drugs Made in America Acquisition in Q2 2026 was UBS Group AG (+2 shares).
• The biggest cuts to DMIIU positions during Q2 2026 came from Clear Street Group Inc. (-158.56K shares), Rangeley Capital, LLC (-23.06K shares) and HRT Financial LP (-275 shares).
• Drugs Made in America Acquisition's 10 largest institutional shareholders as of Q2 2026 were LMR Partners LLP (2Mn shares), Westchester Capital Management, LLC (502.91K shares), Verition Fund Management LLC (250K shares), BlueCrest Capital Management Ltd (250K shares), Walleye Capital LLC (100K shares), L1 Global Manager Pty Ltd (100K shares), Readystate Asset Management LP (100K shares), HRT Financial LP (99.72K shares), Rangeley Capital, LLC (32.55K shares) and Clear Street Group Inc. (8.08K shares), per Business Quant data.